Joseph H. Wender - 01 Dec 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 01 Dec 2025
Net transaction value: -$2,262,848
SEC form: 4
Accepted by SEC: 03 Dec 2025, 19:01:07 UTC
Prior SEC filing: 20 Nov 2025
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Joseph H. Wender

Key filing fact

Joseph H. Wender filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 03 Dec 2025.

Key facts

This page summarizes Joseph H. Wender's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Dec 2025, 19:01.

Change

Previous filing in this sequence was filed on 20 Nov 2025.
Current net transaction value: -$2,262,848.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001073384 Primary reporting owner

WENDER JOSEPH H

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Joseph H. Wender
Signature date: 03 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Sale

Transaction value: $1,659,362
Shares: -20,571
Change %: -32%
Price: $80.67
Shares after: 43,464
Date: 01 Dec 2025
Ownership: by Trust
Footnotes: F1, F2

IONS transaction

Common Stock

Sale

Transaction value: $603,486
Shares: -7,429
Change %: -17%
Price: $81.23
Shares after: 36,035
Date: 01 Dec 2025
Ownership: by Trust
Footnotes: F1, F3

IONS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 16,000
Date: 01 Dec 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.11 to $81.11 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.12 to $81.435 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.